APLS
Apellis Pharmaceuticals Inc
Halal Rating :
Last Price
$30.07
Last updated:
Market Cap
-
7D Change
5.18%
1 Year Change
-54.06%
Company Overview
Industries
Exchange
Next Earnings Date
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on developing innovative therapies for diseases driven by excessive activation of the complement system, a part of the immune system. Their lead product, SYFOVRE™ (pegcetacoplan injection), is approved for treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). They also have EMPAVELI® (pegcetacoplan) for treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $196.83m | $256.64m | - | $12.53m | 0.00% | 4.88% |
| June 30, 2024 | $199.69m | $238.49m | - | $9.36m | 0.00% | 3.92% |
| March 31, 2024 | $172.32m | $241.38m | - | $6.97m | 0.00% | 2.89% |
Company Impact
Help us evaluate Apellis Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.